Multiple Sclerosis (MS)
Multiple sclerosis is a chronic autoimmune disease of the central nervous system — the brain, spinal cord, and optic nerves — in which the immune system mistakenly attacks the myelin sheath, the protective coating that surrounds nerve fibres. This process, known as demyelination, disrupts or blocks the transmission of nerve signals and leads to a wide variety of neurological symptoms. The cause of MS is not fully understood, but it is thought to involve a combination of genetic susceptibility and environmental triggers — including vitamin D deficiency, Epstein-Barr virus infection, and smoking.
Patterns of disease
MS presents differently from person to person, and its course is highly variable. The most common form — relapsing-remitting MS (RRMS) — involves discrete episodes of neurological symptoms (relapses or exacerbations) that typically develop over hours or days, persist for weeks, and then partially or fully recover (remissions). Over time, many people with RRMS transition to secondary progressive MS, in which disability accumulates more steadily. A minority of people have primary progressive MS from the outset, with gradual worsening from the beginning.
Symptoms
Because MS can affect any part of the central nervous system, its symptoms are extraordinarily varied. Common features include fatigue (which many describe as different in character from ordinary tiredness), visual disturbances (particularly optic neuritis, causing pain on eye movement and blurred or lost vision in one eye), limb weakness and spasticity, tingling or numbness, balance and coordination problems, bladder dysfunction, cognitive difficulties (especially with memory and concentration), mood changes, and pain. The pattern and severity of symptoms depends on which areas of the nervous system are affected.
Diagnosis
MS is diagnosed using the McDonald criteria, which incorporate clinical findings, MRI evidence of lesions disseminated in space and time, and cerebrospinal fluid analysis (which may show oligoclonal bands). MRI is the most sensitive tool for detecting demyelinating plaques and monitoring disease activity.
Treatment
Disease-modifying therapies (DMTs) have transformed the management of relapsing MS. These medications — including interferon-beta, glatiramer acetate, natalizumab, ocrelizumab, cladribine, and others — reduce relapse frequency and slow the accumulation of disability. Treatment decisions balance efficacy against safety and individual patient factors. Acute relapses are treated with high-dose intravenous methylprednisolone. Symptom management involves a multidisciplinary approach: physiotherapy for mobility and spasticity, occupational therapy, bladder management, fatigue strategies, pain management, and psychological support.
Choosing where to be treated
Use our independent directory to compare licensed organisations in Turkey, or read our selection guide before you decide.